CASTRES, France and LIVERPOOL, UK I March 6, 2014 I Redx Pharma and Pierre Fabre Laboratories have today completed a collaboration and option agreement in cancer research.
The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.
The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as “a highly significant milestone” in the company’s development.
The Redx Pharma group is focused on early stage drug discovery and development programmes at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-Infectives).
Pierre Fabre, the second largest French pharmaceutical company, enjoys world-class expertise in both oncology and dermatology. Its portfolio is focused on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.
Neil Murray, chief executive, Redx Pharma said: “We are delighted to have reached an agreement with Pierre Fabre, which represents the first major transaction for our anti-cancer subsidiary Redx Oncology. The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits. We look forward to benefitting from Pierre Fabre’s outstanding capabilities in this area and developing a long and successful partnership.”
Christian Bailly, Head of Research at Pierre Fabre Pharmaceuticals, said: “We are looking forward to working with Redx Pharma as part of our commitment to external innovation to complete our cutting-edge R&D capabilities. This collaboration with Redx Oncology, a dynamic and visionary biotech company, marks an additional milestone in our partnering research strategy. Combining our capabilities with Redx researchers will accelerate our drug discovery process.”
“Capitalizing on our proven scientific expertise in oncology, skin cancers represent one of the key axis of our R&D efforts in dermatology”, added Dr Jean-Jacques Voisard, General Manager of Pierre Fabre Dermatologie, the division in charge of Pierre Fabre’s dermatology product portfolio.
About Onco-dermatology
Skin cancers today represent 30% of total cancers. The incidence increases by 5% each year and it is expected a 50% increase of activity among liberal dermatologists, key players in skin cancer care, before 2030. Remarkable progresses have however been made in the last 20 years in the fundamental understanding of cancer, to consider today “smart” treatment of these cancers, with therapies as targeted as possible, in order to limit the morbidity associated with surgery.
SOURCE: Redx Pharma
Post Views: 116
CASTRES, France and LIVERPOOL, UK I March 6, 2014 I Redx Pharma and Pierre Fabre Laboratories have today completed a collaboration and option agreement in cancer research.
The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.
The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as “a highly significant milestone” in the company’s development.
The Redx Pharma group is focused on early stage drug discovery and development programmes at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-Infectives).
Pierre Fabre, the second largest French pharmaceutical company, enjoys world-class expertise in both oncology and dermatology. Its portfolio is focused on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.
Neil Murray, chief executive, Redx Pharma said: “We are delighted to have reached an agreement with Pierre Fabre, which represents the first major transaction for our anti-cancer subsidiary Redx Oncology. The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits. We look forward to benefitting from Pierre Fabre’s outstanding capabilities in this area and developing a long and successful partnership.”
Christian Bailly, Head of Research at Pierre Fabre Pharmaceuticals, said: “We are looking forward to working with Redx Pharma as part of our commitment to external innovation to complete our cutting-edge R&D capabilities. This collaboration with Redx Oncology, a dynamic and visionary biotech company, marks an additional milestone in our partnering research strategy. Combining our capabilities with Redx researchers will accelerate our drug discovery process.”
“Capitalizing on our proven scientific expertise in oncology, skin cancers represent one of the key axis of our R&D efforts in dermatology”, added Dr Jean-Jacques Voisard, General Manager of Pierre Fabre Dermatologie, the division in charge of Pierre Fabre’s dermatology product portfolio.
About Onco-dermatology
Skin cancers today represent 30% of total cancers. The incidence increases by 5% each year and it is expected a 50% increase of activity among liberal dermatologists, key players in skin cancer care, before 2030. Remarkable progresses have however been made in the last 20 years in the fundamental understanding of cancer, to consider today “smart” treatment of these cancers, with therapies as targeted as possible, in order to limit the morbidity associated with surgery.
SOURCE: Redx Pharma
Post Views: 116
